查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1555655

胚胎着床前遗传学的检验(PGT)市场:全球产业分析，规模，占有率，成长，趋势，预测，2024-2031年

Preimplantation Genetic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
出版日期: | 出版商: Persistence Market Research | 英文 177 Pages | 商品交期: 2-5个工作天内

价格
简介目录

Persistence Market Research最近发布了一份有关全球植入前基因检测 (PGT) 市场的详细报告。该报告对市场推动因素、趋势、机会和课题等关键市场动态进行了全面分析，提供了对市场结构的深入见解。

主要的洞察

  • 植入前基因检测 (PGT) 市场规模（2024 年）：6.8 亿美元
  • 预估市场规模（2031 年）：14.8 亿美元
  • 全球市场成长率（2024 年至 2031 年复合年增长率）：9%

植入前基因检测 (PGT) 市场 - 报告范围：

植入前基因检测（PGT）市场涵盖了不孕症治疗中使用的各种基因检测程序，特别是在体外受精（IVF）过程中。植入前基因检测（PGT）可以筛检胚胎是否有遗传疾病，并增加健康怀孕的机会。由于人们对遗传疾病认识的提高、不孕症治疗的进步以及精准健康和个人化医疗的结合，该市场正在不断扩大。 PGT 可应用于多种场合，包括医院、生育诊所和家庭使用。不孕率上升、延迟出生和基因检测技术进步推动了成长。

推动市场成长的因素：

基因技术的进展

次世代定序 (NGS) 和 CRISPR 等基因技术的快速进步是 PGT 市场的关键推动因素。这些技术可以实现更准确、高效和全面的基因筛检，提高胚胎基因异常检测的准确性。 NGS 允许同时分析多个基因，从而减少与基因检测相关的时间和成本。非侵入性检测的发展使准父母更容易接受和接受PGT，从而推动了对更健康怀孕和预防遗传疾病的需求。

不孕​​率上升和生育延迟

不孕​​率上升和分娩延迟的全球趋势对市场成长做出了重大贡献。压力、饮食和环境污染物等生活方式因素与不孕率增加有关。随着越来越多的夫妇选择晚育，染色体异常的风险增加，使得PGT成为选择健康胚胎和降低遗传风险的重要工具。随着夫妻寻求确保怀孕的健康和生存能力，人们对辅助生殖技术 (ART) 的认识不断提高，进一步推动了对 PGT 的需求。

接受度与认知度提升

减少不孕症治疗带来的耻辱以及提高对基因检测益处的认识正在推动市场扩张。教育活动、遗传咨询的进步和媒体报告提高了公众意识并促使 PGT 的广泛接受。随着夫妻越来越了解基因筛检的好处，对 PGT 的需求正在增加。保险公司也认识到 PGT 保险的好处，进一步推动市场成长。

市场阻碍因素：

成本高且可访问性有限

PGT 的高成本是市场的主要限制。基因检测所需的复杂技术使得该程序昂贵并限制了其可近性，特别是在医疗基础设施有限的发展中国家。此外，PGT 不受保险保障，这限制了高收入者的使用。这种经济障碍限制了那些能够支付自付费用的人的进入，从而阻碍了市场的成长潜力。

道德与法律问题

基于遗传特征选择胚胎的伦理担忧引发了有关优生学和遗传歧视的复杂问题。这些担忧导致社会动盪和监管课题，影响市场成长。不同地区的监管环境差异很大，一些国家对基因检测实施严格监管或禁止，使市场扩张更加复杂。

市场机会：

个人化医疗与精准健康的融合

个人化医疗的整合为PGT市场带来了重大机会。随着医疗保健越来越多地采用个人化方法，PGT 透过选择基因健康的胚胎无缝地适应了这一趋势。基因组学和人工智慧的进步使 PGT 更加准确和易于使用，满足了对客製化医疗解决方案不断增长的需求。预测遗传风险和客製化治疗计划的能力与现代医疗保健对精确度的强调相一致，为 PGT 市场创造了巨大的成长机会。

本报告涵盖的主要问题

  • 推动全球胚胎植入前基因检测 (PGT) 市场发展的关键因素有哪些？
  • 推动植入前基因检测 (PGT) 市场的程序和应用有哪些？
  • 科技进步如何形塑竞争格局？
  • 市场上的主要参与者有哪些？
  • 全球PGT市场的新趋势和未来前景是什么？

目录

第1章 摘要整理

第2章 市场概要

  • 市场范围和定义
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
    • 主要趋势
  • 宏观经济要素
    • 全球各部门展望
    • 全球GDP成长预测
    • 全球医疗保健支出预测
  • COVID-19影响分析
  • 预测要素- 相关性及影响

第3章 附加价值的洞察

  • 流行病学-疾病的得病率和发生率
  • 技术评估
  • 法规情形
  • 价值链分析
  • 主要的交易与合併
  • 大环境分析
  • 波特的五力分析

第4章 全球胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

  • 主要的焦点
    • 市场规模(金额)和与前一年同期比较成长率
    • 绝对的商机
  • 市场规模(金额)的分析与预测
    • 过去的市场规模(金额)分析，2019年～2023年
    • 目前市场规模(金额)分析与预测，2023～2031年
  • 全球胚胎着床前遗传学的检验(PGT)市场展望:检验类型
    • 简介/主要调查结果
    • 过去的市场规模(金额)分析，检验各类型，2019～2023年
    • 目前市场规模(金额)分析与预测，检验各类型，2024～2031年
      • 诊断
      • 筛检
  • 市场魅力分析:检验类型
  • 全球胚胎着床前遗传学的检验(PGT)市场展望:技术
    • 简介/主要调查结果
    • 过去的市场规模(金额)分析，各技术，2019～2023年
    • 目前市场规模(金额)分析与预测，各技术，2024～2031年
      • CGH为基础的
      • FISH为基础的
      • NGS为基础的
      • SNP为基础的
      • PCR为基础的
  • 市场魅力分析:技术
  • 全球胚胎着床前遗传学的检验(PGT)市场展望:终端用户
    • 简介/主要调查结果
    • 过去的市场规模(金额)分析，各终端用户，2019～2023年
    • 目前市场规模(金额)分析与预测，各终端用户，2024～2031年
      • 感染疾病
      • 神经疾病
      • 自体免疫疾病
      • 肿瘤学
      • 其他
  • 市场魅力分析:终端用户

第5章 全球胚胎着床前遗传学的检验(PGT)市场展望:地区

  • 主要的焦点
  • 过去的市场规模(金额)分析，各地区，2019～2023年
  • 目前市场规模(金额)分析与预测，各地区，2024～2031年
    • 北美
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 南美
    • 中东·非洲
  • 市场魅力分析:地区

第6章 北美的胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

第7章 欧洲的胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

第8章 东亚的胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

第9章 南亚及大洋洲的胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

第10章 南美的胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

第11章 中东及非洲的胚胎着床前遗传学的检验(PGT)市场展望:过去(2019年～2023年)及预测(2024年～2031年)

第12章 竞争情形

  • 市场占有率分析，2023年
  • 市场结构
    • 各市场的竞争激烈化地图
    • 竞争仪表板
  • 企业简介(详细内容- 概要，财务，策略，最近的趋势)
    • Agilent Technologies Inc.
    • Abbott Laboratories
    • CooperSurgical Inc.
    • Oxford Gene Technology IP
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • PerkinElmer Inc.
    • Genea Limited
    • Natera Inc.
    • Rubicon Genomics Inc.
    • CombiMatrix Corporation

第13章 附录

  • 调查手法
  • 调查的前提条件
  • 缩写和简称
简介目录
Product Code: PMRREP34757

Persistence Market Research has recently published an extensive report on the global Preimplantation Genetic Testing (PGT) Market. This report offers a comprehensive analysis of key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Preimplantation Genetic Testing Market Size (2024E): USD 0.68 Bn
  • Projected Market Value (2031F): USD 1.48 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 9%

Preimplantation Genetic Testing Market - Report Scope:

The Preimplantation Genetic Testing (PGT) Market covers a range of genetic testing procedures used in fertility treatments, particularly in in-vitro fertilization (IVF) processes. PGT allows for the screening of embryos for genetic disorders, increasing the chances of healthy pregnancies. The market is expanding due to the rising awareness of genetic disorders, advancements in fertility treatments, and the integration of precision health and personalized medicine. PGT finds applications in various settings, including hospitals, fertility clinics, and home use. The growth is driven by increasing infertility rates, delayed childbearing, and technological advancements in genetic testing.

Market Growth Drivers:

Advances in Genetic Technology

Rapid advancements in genetic technology, such as next-generation sequencing (NGS) and CRISPR, are key drivers of the PGT market. These technologies allow for more accurate, efficient, and comprehensive genetic screening, improving the precision of detecting genetic anomalies in embryos. NGS enables the analysis of multiple genes simultaneously, reducing both time and costs associated with genetic testing. The development of non-invasive testing methods is making PGT more accessible and acceptable to prospective parents, driving demand for healthier pregnancies and the prevention of genetic disorders.

Rising Infertility Rates and Delayed Childbearing

Increasing infertility rates and a global trend towards delayed childbearing are contributing significantly to the market's growth. Lifestyle factors, including stress, diet, and environmental pollutants, are leading to higher infertility rates. As more couples opt to have children later in life, the risk of chromosomal abnormalities increases, making PGT a critical tool for selecting healthy embryos and reducing genetic risks. The growing awareness of assisted reproductive technologies (ART) is further boosting demand for PGT, as couples seek to ensure the health and viability of their pregnancies.

Growing Acceptance and Awareness

Increasing awareness of the benefits of genetic testing, along with the decreasing stigma surrounding fertility treatments, is driving market expansion. Educational campaigns, advancements in genetic counseling, and media coverage are raising public awareness, leading to a broader acceptance of PGT. As couples become more informed about the benefits of genetic screening, demand for PGT rises. Insurance companies are also recognizing the benefits of covering PGT, further driving market growth.

Market Restraints:

High Costs and Limited Accessibility

The high costs associated with PGT are a significant restraint on the market. The advanced technologies required for genetic testing make the procedure expensive, limiting its accessibility, particularly in developing countries with limited healthcare infrastructure. The lack of insurance coverage for PGT also limits its accessibility to higher-income individuals. This financial barrier hampers the market's growth potential by restricting access to those who can afford the out-of-pocket expenses.

Ethical and Legal Concerns

Ethical concerns regarding the selection of embryos based on genetic characteristics raise complex questions about eugenics and genetic discrimination. These concerns lead to public apprehension and regulatory challenges, which impact the market's growth. Regulatory environments vary significantly across regions, with some countries imposing strict regulations or bans on genetic testing, further complicating market expansion.

Market Opportunities:

Integration of Personalized Medicine and Precision Health

The integration of personalized medicine presents a significant opportunity for the PGT market. As healthcare increasingly adopts personalized approaches, PGT fits seamlessly into this trend by enabling the selection of genetically healthy embryos. With advancements in genomics and artificial intelligence, PGT is becoming more accurate and accessible, meeting the growing demand for tailored healthcare solutions. The ability to predict genetic risks and customize treatment plans aligns with modern healthcare's focus on precision, creating substantial growth opportunities in the PGT market.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Preimplantation Genetic Testing (PGT) Market?
  • Which procedures and applications are leading in the PGT market?
  • How are technological advancements shaping the competitive landscape?
  • Who are the key players in the market, and what strategies are they employing?
  • What are the emerging trends and future prospects for the global PGT market?

Competitive Intelligence and Business Strategy:

Key players in the global Preimplantation Genetic Testing Market are focusing on research and development to innovate and enhance their product offerings. Companies are investing in advanced technologies like AI for genetic analysis, making PGT more efficient and accessible. Collaborations with fertility clinics and hospitals are strengthening their market presence. Emphasis on consumer education and marketing strategies fosters growth and brand loyalty in the evolving PGT market landscape.

Key Market Players

  • Quest Diagnostics Incorporated
  • Natera, Inc.
  • COOPER SURGICAL, INC.
  • Genea Pty Limited.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Bioarray S.L.
  • Illumina, Inc.
  • Igenomix
  • RGI
  • F. Hoffmann-La Roche Ltd.

Market Segmentation

By Procedure

  • Genetic Diagnosis
  • Genetic Screening

By Product

  • Reagents
  • Instruments

By Technology

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)

By Region

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • The Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Preimplantation Genetic Testing Market Snapshot, 2024-2031
  • 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Epidemiology - Disease Prevalence and Incidence
  • 3.2. Technology Assessment
  • 3.3. Regulatory Landscape
  • 3.4. Value Chain Analysis
  • 3.5. Key Deals and Mergers
  • 3.6. PESTLE Analysis
  • 3.7. Porter's Five Force Analysis

4. Global Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
  • 4.3. Global Preimplantation Genetic Testing Market Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
      • 4.3.3.1. Diagnostics
      • 4.3.3.2. Screening
  • 4.4. Market Attractiveness Analysis: Test Type
  • 4.5. Global Preimplantation Genetic Testing Market Outlook: Technology
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
      • 4.5.3.1. CGH-based
      • 4.5.3.2. FISH-based
      • 4.5.3.3. NGS-based
      • 4.5.3.4. SNP-based
      • 4.5.3.5. PCR-based
  • 4.6. Market Attractiveness Analysis: Technology
  • 4.7. Global Preimplantation Genetic Testing Market Outlook: End User
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
      • 4.7.3.1. Infectious Diseases
      • 4.7.3.2. Neurological Diseases
      • 4.7.3.3. Autoimmune Diseases
      • 4.7.3.4. Oncology
      • 4.7.3.5. Others
  • 4.8. Market Attractiveness Analysis: End User

5. Global Preimplantation Genetic Testing Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By Technology
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 6.4.1. Diagnostics
    • 6.4.2. Screening
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 6.5.1. CGH-based
    • 6.5.2. FISH-based
    • 6.5.3. NGS-based
    • 6.5.4. SNP-based
    • 6.5.5. PCR-based
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 6.6.1. Hospitals
    • 6.6.2. Diagnostic Labs
    • 6.6.3. Research & Academic Institutions
    • 6.6.4. Specialized Clinics
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By Technology
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 7.4.1. Diagnostics
    • 7.4.2. Screening
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 7.5.1. CGH-based
    • 7.5.2. FISH-based
    • 7.5.3. NGS-based
    • 7.5.4. SNP-based
    • 7.5.5. PCR-based
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 7.6.1. Hospitals
    • 7.6.2. Diagnostic Labs
    • 7.6.3. Research & Academic Institutions
    • 7.6.4. Specialized Clinics
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By Technology
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 8.4.1. Diagnostics
    • 8.4.2. Screening
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 8.5.1. CGH-based
    • 8.5.2. FISH-based
    • 8.5.3. NGS-based
    • 8.5.4. SNP-based
    • 8.5.5. PCR-based
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 8.6.1. Hospitals
    • 8.6.2. Diagnostic Labs
    • 8.6.3. Research & Academic Institutions
    • 8.6.4. Specialized Clinics
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By Technology
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 9.4.1. Diagnostics
    • 9.4.2. Screening
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 9.5.1. CGH-based
    • 9.5.2. FISH-based
    • 9.5.3. NGS-based
    • 9.5.4. SNP-based
    • 9.5.5. PCR-based
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 9.6.1. Hospitals
    • 9.6.2. Diagnostic Labs
    • 9.6.3. Research & Academic Institutions
    • 9.6.4. Specialized Clinics
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By Technology
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 10.4.1. Diagnostics
    • 10.4.2. Screening
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 10.5.1. CGH-based
    • 10.5.2. FISH-based
    • 10.5.3. NGS-based
    • 10.5.4. SNP-based
    • 10.5.5. PCR-based
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 10.6.1. Hospitals
    • 10.6.2. Diagnostic Labs
    • 10.6.3. Research & Academic Institutions
    • 10.6.4. Specialized Clinics
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Preimplantation Genetic Testing Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By Technology
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2024-2031
    • 11.4.1. Diagnostics
    • 11.4.2. Screening
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2024-2031
    • 11.5.1. CGH-based
    • 11.5.2. FISH-based
    • 11.5.3. NGS-based
    • 11.5.4. SNP-based
    • 11.5.5. PCR-based
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2031
    • 11.6.1. Hospitals
    • 11.6.2. Diagnostic Labs
    • 11.6.3. Research & Academic Institutions
    • 11.6.4. Specialized Clinics
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping by Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Agilent Technologies Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Abbott Laboratories
    • 12.3.3. CooperSurgical Inc.
    • 12.3.4. Oxford Gene Technology IP
    • 12.3.5. Illumina Inc.
    • 12.3.6. Thermo Fisher Scientific Inc.
    • 12.3.7. PerkinElmer Inc.
    • 12.3.8. Genea Limited
    • 12.3.9. Natera Inc.
    • 12.3.10. Rubicon Genomics Inc.
    • 12.3.11. CombiMatrix Corporation

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations